Inflammatory bowel disease
Jul 12, 2024
Eli Lilly strengthening its Gastroenterology portfolio post Acquisition of Morphic. Tracking competitors and alliances in inflammatory bowel disease (IBD).
In a strategic move aimed at bolstering its portfolio in inflammatory bowel disease (IBD) treatments, Eli Lilly and Company has announced a definitive agreement to acquire Morphic Holding for approximately USD 3.2 billion. The purchase price represents a 79% premium to Morphic’s closing stock price. Post the tender...
Read More...
Apr 24, 2024
From Science Fiction to Reality: Investigating the Market Dynamics and Growing Demand for the Smart Pills
Over the past few years, the evolution of Smart Pills has been remarkable, driven largely by advancements in technology and innovative developments in healthcare. These pills, equipped with sensors, microprocessors, and wireless communication capabilities, have revolutionized the field of medicine. Technological in...
Read More...
Mar 26, 2024
Regeneron’s Odronextamab BLA; Novo Nordisk’s Cardior Pharmaceuticals Acquisition; Novartis’ Fabhalta CHMP Approval; Idorsia’s TRYVIO FDA Approval; AbbVie’s Landos Biopharma Acquisition
Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and...
Read More...
Nov 28, 2023
Dupixent Significantly Reduced COPD Exacerbations; Sosei Heptares to Regain Ownership of GSK4381406; AstraZeneca Gains Rights to Usynova’s KRAS Inhibitor; FDA Approvs OGSIVEO for Desmoid Tumors; Orphan Drug Designation for ARCT-032 for the Cystic Fibrosis; FDA Fast Track Designation for ADP101 for Food Allergies
Dupixent Significantly Reduced COPD Exacerbations In Second Positive Phase III Trial The latest trial for Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD), called NOTUS, has delivered promising results. It showed a significant 34% reduction in COPD exacerbations, confirming earlier positive f...
Read More...
Oct 10, 2023
Amgen to Acquire Horizon Therapeutics; Sanofi and Teva Announce Collaboration; Boehringer Obesity Drug Trial Update; FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL; Anaptys Announces Phase 3 Clinical Trial Results of Imsidolimab; Orphan Drug Designation to GC Biopharma’s GC1126A
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment Sanofi and Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, have announced a collaboration to co-develop and co-commercialize asset TEV'574, which is currently in Phase ...
Read More...
Mar 02, 2023
Eko’s AI-powered Sensora Platform; SOPHiA GENETICS and QIAGEN Announced Partnership; Co-Diagnostics’s At-Home and Point-of-Care Co-Dx PCR Home™ Platform; Abbott’s Minimally Invasive Heart Devices Updates; SpectraWAVE’s HyperVue™ Intravascular Imaging System; FDA Approval to Bioelectronic Medicine’s Bioelectric Technology
AI-powered Sensora Platform Launched by Eko for Cardiac Disease Detection On February 23, 2023, Eko, a digital healthcare company employing artificial intelligence (AI) against heart and lung disease, announced the launch of its SENSORA™ Cardiac Disease Detection Platform. The stethoscope, one of the m...
Read More...
May 18, 2022
Evaluating the Major Developments in the Smart Pills Market
As our medical demands rise, so does the technology that distributes our medications. With innovative phone apps, alarms, smart packaging, and smart pills, there is no excuse to miss a dosage or forget to take your medication. With the evolution of wireless devices and microscopic cameras, the terms "embeddable" an...
Read More...
Jul 09, 2020
Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates
Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclisa. The deal worth of USD 986 million gives the global rights to Sanofi for therapies that could lessen an efficacy-limit...
Read More...
Feb 21, 2019
Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M
Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised USD 150 million. Peloton’s lead therapeutic candidate, PT2977, focuses on targeting hypoxia-inducible fac...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
